US equities |
INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% MU $934.27 ▲+0.00% NVDA $213.66 ▲+0.00% SKHY $162.09 ▲+0.00% GOOGL $283.82 ▲+0.00% AMZN $243.79 ▲+0.00% TSLA $403.30 ▲+0.00%
FinancialContent

Heartbeam, Inc. - Common Stock (NQ:BEAT)

0.5389 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Heartbeam, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
From HeartBeam, Inc.
Via Business Wire
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
News headline image
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT)
Via Get News
Topics Intellectual Property
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Technology
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
From HeartBeam, Inc.
Via Business Wire
News headline image
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Partner to Advance Remote ECG Monitoring
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
From HeartBeam, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 13, 2025 ↗
 
Via Benzinga
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam Announces Exercise and Closing of Underwriter’s Over-Allotment Option for Public Offering of Common Stock
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Prices $10 Million Public Offering at $1.70 Per Share
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference
Via Investor Brand Network
Topics Intellectual Property
News headline image
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
From HeartBeam, Inc.
Via Business Wire
News headline image
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Technology at AHA Conference
Via Investor Brand Network
News headline image
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Cardiac Care Technology with FDA Submissions and Key Leadership Appointments
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >